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Abstract
Background: Outcomes for patients in UK with locally advanced non-small cell lung cancer (LA NSCLC) are
amongst the worst in Europe. Assessing outcomes is important for analysing the effectiveness of current practice.
However, data quality is inconsistent and regular large scale analysis is challenging.
This project investigates the use of routine healthcare datasets to determine progression free survival (PFS) and
overall survival (OS) of patients treated with primary radical radiotherapy for LA NSCLC.
Methods: All LA NSCLC patients treated with primary radical radiotherapy in a 2 year period were identified and
paired manual and routine data generated for an initial pilot study. Manual data was extracted information from
hospital records and considered the gold standard. Key time points were date of diagnosis, recurrence, death or
last clinical encounter. Routine data was collected from various data sources including, Hospital Episode Statistics,
Personal Demographic Service, chemotherapy data, and radiotherapy datasets. Relevant event dates were defined
by proxy time points and refined using backdating and time interval optimization. Dataset correlations were then
tested on key clinical outcome indicators to establish if routine data could be used as a reliable proxy measure for
manual data.
Results: Forty-three patients were identified for the pilot study. The manual data showed a median age of 67 years
(range 46- 89 years) and all patients had stage IIIA/B disease. Using the manual data, the median PFS was 10.
78 months (range 1.58–37.49 months) and median OS was 16.36 months (range 2.69–37.49 months). Based on
routine data, using proxy measures, the estimated median PFS was 10.68 months (range 1.61–31.93 months) and
estimated median OS was 15.38 months (range 2.14–33.71 months). Overall, the routine data underestimated the
PFS and OS of the manual data but there was good correlation with a Pearson correlation coefficient of 0.94 for
PFS and 0.97 for OS.
Conclusions: This is a novel approach to use routine datasets to determine outcome indicators in patients with LA
NSCLC that will be a surrogate to analysing manual data. The ability to enable efficient and large scale analysis of
current lung cancer strategies has a huge potential impact on the healthcare system.
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Background
Lung cancer is a leading cause of cancer-related mortal-
ity world-wide with approximately 70% of patients pre-
senting with locally advanced or metastatic disease [1].
In the UK, outcomes for patients with LA NSCLC are
amongst the worst in Europe and local recurrence oc-
curs in up to 50% of patients despite improvements in
5 year survival [2, 3]. This has highlighted a need to not
only identify causes of this deficit and advance treatment
strategies, but a need for frequent large scale analysis of
outcomes to assess the effectiveness of such treatments.
Radiotherapy plays an important role in the treatment
of patients with locally advanced disease and national
cancer strategies have been implemented to incentivize
centres to formally assess radiotherapy outcomes with
the introduction of an outcomes-based commissioning
framework [4]. As a result, there is a recognised need to
be able to assess, qualify and quantify the quality of
radiotherapy practice which is valuable for research and
strategic planning of service provision.
Progression free survival (PFS) and overall survival
(OS) are key outcome measures for lung cancer that are
important assessment tools of the effectiveness of an in-
stitution’s lung cancer strategy. PFS has become an in-
creasingly important outcome measure in clinical trials,
used as a surrogate for OS that is less influenced by sub-
sequent therapies, and important for evaluating treat-
ment response. Measuring PFS is in itself a challenge
due to an inconsistency of definition and use in the
literature and measurement accuracy [5, 6]. To reliably
determine these outcomes measures, the quality, com-
pleteness and consistency of data recording is important
as well as the ability to efficiently interpret these. Manu-
ally collected prospective data taken from patients’
notes, as collected in trials, is considered the gold stand-
ard in most accurately identifying clinically significant
dates for patients’ investigation and management path-
ways. However, data quality can be inconsistent and col-
lecting it is labour- intensive, making assessment of
large numbers time-consuming. Routine datasets are na-
tionally collected patient data, including hospital epi-
sodes statistic (HES), radiotherapy database (RTDS),
systemic anti-cancer therapy (SACT) and personal
demographics service (PDS).
Information from routinely collected electronic data-
sets is inexpensive and its use in population- based stud-
ies to investigate disease incidence, mortality and public
health issues has long been established. There has been
growing interest in using routine data to assess clinical
outcomes [7], particularly in cancer management, in the
hope that regular feedback will facilitate improved out-
comes [8–12]. Whilst dates of diagnosis and recurrence
may not be directly captured in the data it is possible to
identify information to serve as surrogates for these
relevant time points and Ricketts et al. recently demon-
strated that routine data could be used to estimate OS
and PFS in patients with head and neck cancers treated
with radical radiotherapy [13, 14].
The aim of this paper is to develop and optimise a
methodology to extract OS and PFS from routinely col-
lected electronic healthcare data for patients treated with
primary radical radiotherapy for LA NSCLC that will
enable information to be evaluated effectively and
efficiently.
Methods
All patients with LA NSCLC, taken to be any patient
with stage IIIA/B disease (Additional file 1), treated with
primary radical radiotherapy in a 2 year period (August
2013 to August 2015) in University College London
Hospital, a regional referral centre, were identified for
this initial pilot study of 43 patients.
For each patient, paired manual and routine datasets
were generated to compare OS and PFS, based on man-
ual data, with estimated OS and PFS based on routine
data.
Manual dataset
The manual data was extracted from hospital notes
which included clinic letters, multidisciplinary team
(MDT) meetings, histopathology and radiology reports,
and chemotherapy and radiotherapy treatment records.
The relevant time points required to calculate PFS and
OS were the date of diagnosis, recurrence, and death or
last known appointment.
a. Manual diagnosis date: The diagnostic biopsy date
was chosen to most accurately represent the date of
diagnosis as this is when histological confirmation
of disease is obtained. If the biopsy date was not
available (eg. if the biopsy was performed in a
different hospital) then other dates were used
following a hierarchy, as defined by the UK
National Lung Cancer Audit, of date of: i) imaging
in the form of CT (computed tomography) and
PET CT (positron emissions tomography CT) ii)
admission to hospital due to this malignancy iii)
patient’s evaluation at an out-patient clinic relating
to this malignancy and iv) referral [15] (Table 1).
Manual recurrence date: The recurrence date was
taken to be the date of recognized progression,
recurrence, metastases, death, or last known clinical
encounter (if no progression occurred). Progression,
recurrence or metastatic disease was determined by
dates of any investigative procedure, including
radiological scans or biopsies, which first positively
identified disease recurrence (Table 1).
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Routine dataset
Routine data was collected from HES, SACT, RTDS, and
PDS ( Table 2).
Surrogates were identified as suitable proxy mea-
sures for dates of diagnosis and recurrence events
(Table 1).
Table 1 Definitions of key time points used to calculate PFS and OS for manual data and the ICD-10 (international classification of
diseases) and OPCS (Office of population censuses and surveys classification of surgical operations and procedures) codes used for
diagnosis and recurrence flag events from the routine data
Time points Definitions for manual data Definitions for routine data
Diagnosis date In order of preference [15]:
❖ Date of first histological or cytological
confirmation of malignancy.
- date when specimen taken
- date of receipt by pathologist
- date of pathology report
❖ Date of imaging from a CT, PET scan or other
form of clinical diagnosis
❖ Date of admission to hospital because of this
malignancy.
❖ When evaluated at an oncology out-patient
clinic only: date of first consultation at out-
patient clinic because of this malignancy
❖ Date of referral
HES
❖ Date of biopsy (taken as the optimal date of
diagnosis) within pre-specified time window of
X weeks of treatment initiation
If not available, then the earliest within a pre-
specified time window of X weeks of treatment
initiation:
HES
❖ First relevant ICD10 code (Additional file 4)
❖ OPCS identifying relevant time points and
proxy measures for investigation (Additional file 2)
and management (Additional file 3)
RTDS
❖ Date of request on booking form consent date
for secondary treatment. (This date must
correspond to treatment that is also




Recurrence date Any of the following that first positively identifies
recurrent, progressive or metastatic disease:
❖ Date of radiological scan identifying recurrence,
progressive, or metastatic disease
❖ Date of biopsy procedure confirming
recurrence
❖ Date of clinic if a clinical diagnosis of
recurrence, progressive, or metastatic disease is
made and no scans or biopsies undertaken
The earliest within a pre-specified time window of X
weeks of *secondary treatment initiation:
HES
❖ ICD10 codes for secondary malignancies
(Additional file 5)
❖ OPCS and ICD10 codes identifying relevant
time points and proxy measures for recurrent,
progressive or metastatic disease investigation
(Additional file 6).
RTDS
❖ Date of request on booking form consent date.
(This date must correspond to treatment that is
also documented in the RTDS with “Category:
Palliative”
If there are no secondary treatment codes
(Additional file 7) but there are ICD10 codes for
secondary malignancies (Additional file 5), these can
be used to identify recurrence dates.
If there are no ICD10 codes for secondary
malignancies or investigative procedures then the
start date of secondary treatment can be used:
HES
❖ OPCS identifying secondary management for






Death date ❖ Date of recorded death from medical notes or
clinical letters
❖ Date of recorded death on PDS
Endpoint if no recurrence or death ❖ Last known clinical encounter with any
specialty (in the hospital or community) based
on clinical letters or letters of correspondence
from the patient or their next of kin
❖ Date of last HES, SACT, RTDS entry.
* Secondary treatment is defined as any treatment being initiated 10 weeks following completion of primary treatment, identified using relevant codes
(Additional file 7)
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a. Routine diagnosis date: This was taken to be the
corresponding date of biopsy OPCS codes
(Additional file 2) (available for all patients
investigated within our centre), so long as it fell
within a pre-specified time window of x weeks of
lung cancer treatment initiation (Additional file 3)
(see section “Interval definitions for back-dating”). If
biopsy codes were not found on routine data, proxy
time points were used as surrogates as long as they
occurred within this pre-specified time window
from start of primary treatment: the earliest of (i)
the first relevant ICD10 codes denoting lung
malignancy (Additional file 4) or (ii) other
investigative OPCS codes (Additional file 2).
b. Routine recurrence date: The date of progression,
recurrence or metastases was identified using (i)
ICD 10 codes for secondary malignancies
(Additional file 5) or investigative procedures
(Additional file 6) which occurred within a pre-
specified time window prior to secondary treatment
(Additional file 7) initiation (ii) ICD10 codes
identifying secondary malignancies if no secondary
treatment codes appeared (iii) the start date of
secondary treatment if no ICD10 codes for
secondary malignancies or investigative procedures
were seen on routine data.
Secondary treatment was defined as any treatment
event occurring more than 10 weeks after the end of pri-
mary treatment (last day of radiotherapy or chemother-
apy, whichever occurred last) and further identified by
OPCS codes in Additional file 7.
Survival intervals
PFS was taken to be the time interval between the diag-
nosis date and the date of progression, recurrence or
metastases. If no progression occurred the date of last
known clinical encounter or death was used.
OS was taken to be the time interval between the diag-
nosis date to the date of death from any cause or date of
last known clinical encounter (if the patient was still
alive at the time of analysis).
Key code tables were generated to aid interpretation of
the routine data (Additional files 2, 3, 4, 5, 6 and 7), en-
abling the identification of codes signifying the relevant
time points. The datasets were analysed separately in
this manner and then merged to create a timeline.
Table 2 Routine datasets. This shows the national datasets available for analysis, their intended function and the patient-specific
information that can be collected from the different databases
Routine dataset Information available
PDS (Personal Demographics Service)
National electronic database and component part of the NHS




• Date of birth
• NHS Number
• Date of death
HES (Hospital Episodes Statistics)
Patient care data of all patients treated by the NHS in England
(including private patients treated in NHS hospitals and patients
resident outside England receiving treatment funded by the
NHS)
• Dates of all hospital encounters including admissions and







• Area of patient’s residence
SACT (Systemic Anti-Cancer Therapy)
Clinical management information on patients undergoing
chemotherapy in (or funded by) the NHS in England.
• Demographics- including commissioner and provider
initiating treatment
• Clinical status-diagnosis, performance status, treatment
intent
• Programme and regimen- drug details, cycle and regime
number, supportive medications, treatment dates
• Outcome- regimen modification eg. dose reductions, cycle
delays, early termination of treatment, and outcome
summary.
RTDS (Radiotherapy Dataset)
Clinical management information on patients undergoing
radiotherapy treatment collected locally by radiotherapy centres
and submitted to the National Clinical Analysis and Specialised
Applications Team.
• Demographics- commissioner and provider initiating
treatment
• Clinical status- diagnosis, treatment intent, history of
previous radiotherapy (diagnosis relating to that treatment,
treatment intent, dose, fractionation, site treated, dates of
referral and of treatment).
• Dose prescription- dose and fractionation regime, treatment
site
• Outcome- actual dose delivered, treatment dates
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Code identification and classification
Codes were identified and sorted according to diagnostic
ICD 10 codes consistent with lung malignancy (Additional
files 4 and 5) and OPCS codes consistent with diagnostic
investigations (including biopsies and CT or CT PET
imaging) (Additional files 2 and 6) and management strat-
egies (Additional files 3 and 7), separated into radiother-
apy, chemotherapy and interventional treatment.
a. ICD-10 codes indicating primary site lung
malignancies (Additional file 4)
All codes relating to “malignant neoplasm of bronchus
or lung” [C34], “malignant neoplasm of heart, mediasti-
num and pleura” [C38], and “Secondary and unspecified
malignant neoplasm of intrathoracic lymph nodes”
[C77.1] were identified as the majority of patients with
LA NSCLC have mediastinal lymph node involvement.
The additional code, “Abnormal findings on diagnostic
imaging of lung” [R91] was included given the first suspi-
cion of lung malignancy arises from abnormalities seen on
chest x-rays or CTs, acknowledging this does not confirm
diagnosis.
b. OPCS codes identified for primary diagnostic event
(Additional file 2)
Codes identified as surrogates for the diagnosis of
LA NSCLC included biopsies of the lung, pleura and
mediastinal lymph nodes and procedures whereby
specimens are obtained for cytological confirmation of
malignancy. Imaging with body and head CT and
PET CT are important for staging of disease and
glomerular filtration rate testing is standardly
performed for any patient being considered for
chemotherapy.
c. OPCS codes identifying primary management
(Additional file 3)
Primary management codes included those denoting
treatment with radical radiotherapy (identified as inten-
sity modulated radiotherapy [X67.1] and complex
conformal radiotherapy [X67.7]) and chemotherapy.
Interventional codes included endovascular stent place-
ment [L76.9] and insertion of stent into vena cava [L79.3]
(which means the patient experienced superior vena
cava obstruction secondary to a locally advanced
tumour in the lung apex) and required treatment with
stent insertion.
d. ICD-10 codes indicating secondary site
malignancies or complications from recurrent/
progressive/ metastatic disease (Additional file 5)
The codes identified for the diagnosis of recurrent,
progressive or metastatic disease mostly included those
with “Secondary & unspecified malignant neoplasm of-”
as this implies that malignant disease has metastasized
to this site; and codes that identified complications from
metastases, such as cerebral oedema [G93.6], which can
result from cerebral metastases. Additionally, there were
codes that overlapped with those identifying primary
presentation as recurrent and metastatic disease can
present with similar complications depending on the
location of disease.
e. OPCS codes identified for recurrent, progressive or
metastatic disease diagnostic event (Additional file 6)
Codes identified as surrogates for the diagnosis of
recurrent, progressive or metastatic disease over-
lapped codes for primary presentation, as biopsies
are used to confirm recurrence and imaging is used
to re-stage disease. Additional imaging OPCS codes
included those denoting MRI spines ([U211 AND
Z06.1], [U21.1 AND Z06.2], [U21.1 AND Z99.2],
[U21.1 AND Z06.3]) and bone scans [U14.1], as
these are not routinely done at initial staging but are
performed to investigate metastases to the spine and
bones, respectively.
f. OPCS codes identifying secondary management for
recurrent, progressive or metastatic disease
(Additional file 7)
Radiotherapy OPCS codes for “simple radiotherapy”
([X67.5], [Y91.2]) were used as they indicate that treat-
ment is non- curative (as opposed to “complex radio-
therapy” [X67.7], which indicates treatment is radical
with the intention of cure). The only exception to this
rule is that “Preparation for intensity modulated radi-
ation therapy” [X67.1] (considered complex radiotherapy
that is usually delivered in the radical setting) is also
used to code for SABR (stereotactic ablative radiother-
apy), which can be used to treat oligometastatic (single
or few systemic metastases that are amenable to surgery
or ablative therapy) disease.
For chemotherapy OPCS codes, only “Delivery of ex-
clusively oral chemotherapy for neoplasm” [X73.1] is
exclusive to patients being treated for recurrent or meta-
static disease because there are no oral chemotherapy
drugs currently used in the radical setting. The SACT
data can be used in conjunction with the OPCS codes as
it details the specific chemotherapy drugs delivered to
patients and this information can be used to help dis-
criminate curative or non-curative (palliative) treatment
as some drug regimens are used exclusively as palliative
treatment.
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Interventional codes for endovascular stent placement
and insertion of stent into vena cava were also included
here as superior vena cava obstruction can be a compli-
cation of locally recurrent or metastatic disease requiring
treatment with stent insertion.
Interval definitions for back-dating
The process of interval back-dating was used to optimize
the correlation of manual and routine intervals when
using proxy time points from the routine data and filter
out diagnostic events that yielded negative results (Fig. 1).
For the date of diagnosis, a back-dating window of 6 weeks
(1.5 months) was chosen as the interval during which a
diagnostic event might occur prior to the initiation of pri-
mary treatment (denoted by a relevant investigative OPCS
code), or ICD10 code indicating primary diagnosis (which-
ever occurred earliest). If a biopsy OPCS code was avail-
able, this was taken to be the date of diagnosis, so long as
it occurred within 6 weeks prior to the start of primary
treatment, with no further back-dating to other investigate
codes. The same backdating interval was used to identify
the diagnostic events for secondary malignancy presenta-
tion prior to initiation of secondary treatment.
Correlation of these datasets were then tested on the
key clinical outcome indicators of OS and PFS to estab-
lish if routine data could be used as a reliable proxy
measure for manual data.
Results
Patients’ characteristics
We identified 43 consecutive patients for this pilot study, 27
of whom were men and 16 women. Patient demographics
are displayed in Table 3. The median age was 67 years
(range 46- 89 years) and all patients had stage IIIA/B dis-
ease. The majority of patients were PS (performance status)
0–1 but for 6/43 patients the PS was not recorded and 3/43
patients had a PS of 2. 20/43 patients had the optimal cCRT
(concurrent chemoradiotherapy) [16], 9/43 patients had
sCRT (sequential chemoradiotherapy), 13/43 patients had
radical radiotherapy alone, and 1 patient unconventionally
received gefitinib followed by radical radiotherapy (Table 3).
Twenty two patients had adenocarcinomas (18 of
whom had no sensitizing mutations and 3 with unknown
EGFR/ALK status), 19 had squamous cell carcinomas, in
1 patient it was not possible to further differentiate the
tumour beyond determining that it was a NSCLC.1 pa-
tient had no definitive invasive malignancy demonstrated
on biopsy but was treated due to high clinical suspicion.
Survival and recurrence
Using the manual data, the median PFS was 10.78 months
(range 1.58–37.49months) andmedian OS was 16.36months
(range 2.69–37.49 months). Based on the routine data,
using proxy measures, the median PFS was estimated at
10.68 months (range 1.61–31.93 months) and median
Fig. 1 Schematic showing back-dating intervals used for optimization of key time points extracted from routine data. The date of biopsy is taken
to be the date of diagnosis, so long as this date is within a 6 week period of an OPCS code indicating the start of primary treatment. If there is
no biopsy date, then any diagnostic event or relevant ICD 10 code (whichever occurs first) occurring within a 6 week period prior to an OPCS
code indicating the start of primary treatment is taken to be the date of diagnosis of primary disease. For example, an OPCS code for investigative
imaging occurring within 6 weeks prior to treatment, implies there was already clinical suspicion of malignancy at the time of that scan. For the
date of recurrence, progressive or metastatic disease, any diagnostic event or ICD10 code (whichever occurs first) occurring within a 6 week
period prior to an OPCS code indicating the start of secondary treatment is taken to be the date of recurrence. Any treatment event occurring
after 10 weeks after completion of primary treatment was interpreted as secondary treatment. If no secondary treatment has been given then a
secondary malignancy ICD 10 code (Additional file 5) can be used to identify recurrent disease
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Table 3 Patients’ characteristics. NR (Not recorded). PS (Performance status)* (Additional file 8 [21]), EGFR (epidermal growth factor
receptor), EGFR mutation (epidermal growth factor receptor with a sensitizing mutation to targeted therapy), ALK (anaplastic lymphoma
kinase), Kras (K-rat sarcoma), WT (wild type) meaning no sensitizing mutations are found. cCRT (concurrent chemoradiotherapy), sCRT
(sequential chemoradiotherapy). RT (radiotherapy). 4 cycles of chemotherapy are usually given. CV (cisplatin and vinorelbine), CarboV
(carboplatin and vinorelbine), GCis (gemcitabine and cisplatin), GCarb (gemcitabine and carboplatin), Pemcarbo (pemetrexed and
carboplatin), CisN (cisplatin and navelbine). AE (adverse event)
Patient Age range PS Stage Histology Treatment
1 45-49y PS1 IIIA Squamous cell carcinoma cCRT (CVx4; 64Gy in 32#)
2 65-69y PS0 IIIA Squamous cell carcinoma sCRT (GCarb × 4; 64Gy in 32#)
3 70-74y PS1 IIIA Squamous cell carcinoma cCRT (CV ×1-stopped due to AE; 64Gy
in 32#)
4 70-74y PS1 IIIA Squamous cell carcinoma sCRT (GCis ×4; 55 Gy in 20#)
5 80-84y PS1 IIIA Adenocarcinoma. EGFR WT sCRT (pemcarbo ×2- stopped due to AE;
64Gy in 32#)
6 55-59y PS1 IIIA Adenocarcinoma EGFR WT cCRT (CV ×4, 64Gy in 32#)
7 70-74y PS1 IIIB Squamous cell carcinoma sCRT (GCarbo ×3- stopped due to AE;
55Gy in 20#)
8 65-69y PS0 IIIA Squamous cell carcinoma cCRT (CVx3; 55gy in 20#)
9 65-69y NR IIIA Squamous cell carcinoma RT alone: 55gy in 20#
10 55-59y NR IIIA Squamous cell carcinoma RT alone: 64Gy in 32#
11 65-69y NR IIIB Squamous cell carcinoma sCRT (GCisx2 switched to GCarbo x 2
due to AE; 64Gy in 32#
12 65-69y NR IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4, 64Gy in 32#)
13 75-79y PS1 IIIA Adenocarcinoma. EGFR mutation Gefitinib ×6 followed by 55 in 20#
14 65-69y PS0 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CVx1 switched to CarboV ×3 due
to AE; 64Gy in 32#)
15 65-69y PS1 IIIA High grade dysplasia at least; no
definitive invasive malignancy
cCRT (CV ×4; 64Gy in 32#)
16 55-59y PS1 IIIA Squamous cell carcinoma cCRT (CV ×2; 64Gy in 32#)
17 70-74y NR IIIB Adenocarcinoma. EGFR and ALK WT RT alone: 64Gy in 32#
18 75-79y PS0 IIIB Adenocarcinoma. EGFR and ALK WT cCRT (CisN; 64Gyin 32#)
19 80-84y PS2 IIIB Squamous cell carcinoma RT alone: 64Gy in 32#
20 50-54y PS1 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4; 64Gy in 32#)
21 50-54y PS0 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×3; 64Gy in 32#)
22 55-59y PS1 IIIB Adenocarcinoma. EGFR and ALK WT RT alone: 64Gy in 32#
23 70-74y PS1 IIIA Squamous cell carcinoma RT alone: 55Gy in 20#
24 75-79y PS1 IIIA Adenocarcinoma. EGFR and ALK WT sCRT (CVx4; 64Gy in 32#)
25 80-84y PS1 IIIA PD carcinoma(no comment on EGFR/
ALK)
RT alone: 55Gy in 20#
26 60-64y PS0 IIIA Adenocarcinoma. EGFR and ALK WT sCRT (CV ×2 switched to CarboV ×2 due
to AE; 64Gy in 32#)
27 80-84y PS0 IIIA Squamous cell carcinoma cCRT (CV ×4; 64Gy in 32#)
28 45-49y PS1 IIIB Squamous cell carcinoma cCRT (CV ×4; 64Gy in 32#)
29 65-69y PS1 IIIA Squamous cell carcinoma cCRT (CarboVx3; 64Gy in 32#)
30 45-49y PS1 IIIA Adenocarcinoma-insufficient material for
ALK/EGFR testing
sCRT (cispem ×4; 64Gy in 32#)
31 65-69y PS0 IIIA Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4; 64Gy in 32#)
32 60-64y PS1 IIIA Adenocarcinoma. EGFR and ALK WT sCRT (cispemx2 switched to CV ×2 due
to AE; 64Gy in 32#)
33 60-64y PS1 IIIB Squamous cell carcinoma cCRT (CV ×4; 64Gy in 32#)
34 70-74y PS1 IIIB Squamous cell carcinoma RT alone: 64Gy in 32#
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OS was estimated at 15.38 months (range 2.14–33.
71 months) (Fig. 2a and b).
The routine methodology failed to detect 4 recur-
rences and 3 deaths resulting in increased censoring of
events and a separation of the curves that was not statis-
tically significant for either endpoint.
Data correlation
Overall the routine data underestimated the PFS (manual
(mean = 13.88 months, SD = 9.31); routine (mean = 13.
79 months, SD = 8.95) and OS (manual (mean = 16.
49 months, SD = 9.33); routine (mean = 15.48 months, SD
= 9.17) of the manual data. A paired sample t-test for the
mean PFS showed a difference of 0.09 months (p = 0.86;
95% confidence interval − 0.86- 1.03) and 1.02 months
(p = 0.00; 95% confidence interval 0.34–1.69) for the
difference in the mean OS. However, there was good
overall correlation of 0.94 (p = 0.00, 95% confidence inter-
val 0.90–0.97) for PFS (Fig. 3a) and 0.97 (p = 0.00, 95%
confidence interval 0.95–0.98) for OS (Fig. 3b).
The routine methodology correctly identified 32/43 rou-
tine diagnosis dates to within 2 weeks accuracy of the
manual diagnosis dates, and of those, 21/43 dates matched
exactly. 5/43 routine diagnosis dates were earlier than the
manual dates (ranging from 1 to 6 days earlier). 5/43 rou-
tine diagnosis dates were outside of 2 weeks but within
4 weeks of the manual data; and for 6/43 patients, there
was a > 28 day difference in routine and manual diagnosis
dates, with the routine dates occurring later than the
manual. 3 patients had a difference in diagnosis dates
of > 100 days. Whilst the paired sample t test showed
that routine data tend to suggest later diagnosis dates
compared to that identified by manual data (t = − 2.
45; p = 0.02) and the overall correlation was 0.98 (p =
0.00, 95% confidence interval 0.96–0.99) (Fig. 3c).
The sensitivity and specificity of using routine data in-
stead of manual data to determine recurrences was 0.75
and 1, respectively. 12/16 recurrences were correctly de-
tected when assessing the routine data alone. 4/16 rou-
tine recurrence dates were within 2 weeks of the manual
diagnosis dates, and of those, 3/16 dates matched
exactly. 6/16 routine diagnosis dates were outside of
4 weeks but less than 100 days of the manual data. For
2/16 patients, there was a > 100 day difference in routine
and manual diagnosis dates (Fig. 3a).
The sensitivity and specificity of using routine data in-
stead of manual data to determine death event was 0.81
and 1, respectively. 13/16 death events were correctly de-
tected on the routine data and of those, 12/13 dates of
death matched exactly and for the remaining other pa-
tient, the routine date fell within 1 week of the manual
death date. For 27 patients who were still alive at the time
of assessment and for whom the last clinical encounter
was used as the end- interval, the manual and routine
dates matched exactly for 24/27 patients (Fig. 3b).
For patients 13 and 11, diagnosis and chemotherapy
(as part of sCRT) were initiated in other hospitals and
followed-up continued there, resulting in missing clinical
episodes on routine data but detection on manual data
(as clinical correspondence letters were available). The
result was later routine diagnosis dates and shorter over-
all routine PFS and OS. Patient 36 similarly continued
follow-up in another hospital. For patients 23 and 6 a
late routine diagnosis date resulted from positive
diagnostic investigations falling outside the 6 week
Table 3 Patients’ characteristics. NR (Not recorded). PS (Performance status)* (Additional file 8 [21]), EGFR (epidermal growth factor
receptor), EGFR mutation (epidermal growth factor receptor with a sensitizing mutation to targeted therapy), ALK (anaplastic lymphoma
kinase), Kras (K-rat sarcoma), WT (wild type) meaning no sensitizing mutations are found. cCRT (concurrent chemoradiotherapy), sCRT
(sequential chemoradiotherapy). RT (radiotherapy). 4 cycles of chemotherapy are usually given. CV (cisplatin and vinorelbine), CarboV
(carboplatin and vinorelbine), GCis (gemcitabine and cisplatin), GCarb (gemcitabine and carboplatin), Pemcarbo (pemetrexed and
carboplatin), CisN (cisplatin and navelbine). AE (adverse event) (Continued)
Patient Age range PS Stage Histology Treatment
35 60-64y PS1 IIIB Adenocarcinoma. EGFR and ALK WT,
KRAS mutation
cCRT (CV ×4; 64Gy in 32#)
36 45-49y PS1 IIIA NSCLC-not possible to further
differentiate tumour type
cCRT (CV ×4; 64Gy in 32#)
37 70-74y PS2 IIIA Squamous cell carcinoma RT alone: 55Gy in 20#
38 65-69y PS1 IIIB Adenocarcinoma. EGFR and ALK WT cCRT (CV ×4; 64Gy in 32#)
39 55-59y PS1 IIIB Adenocarcinoma. EGFR and ALK WT cCRT (CV ×6; 64Gy in 32#)
40 80-84y PS1 IIIA Adenocarcinoma RT alone: 55Gy in 20#
41 75-79y NR IIIB Adenocarcinoma. EGFR and ALK WT RT alone: 64Gy in 32#; declined
chemotherapy
42 60-64y PS2 IIIA Adenocarcinoma. EGFR and ALK WT RT alone: 55Gy in 20#
43 85-89y PS1 IIIA Squamous cell carcinoma RT alone: 55Gy in 20#
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back-dating interval from treatment and alternative surro-
gates being used, resulting in a shorter PFS and OS. For
patient 38, the routine PFS was shorter as recurrence was
not detected on routine data due to individualised treat-
ment which was not listed as a standard treatment code.
Discussion
In this pilot study, we analyzed the PFS and OS for
43 patients with LA NSCLC treated in our regional
referral centre in north London over a 2 year period.
The results suggest that routine data can potentially
be used to reliably estimate survival outcomes for
patients with LA NSCLC treated with primary radical
radiotherapy. This method relies on identifying rele-
vant ICD-10 and OPCS codes that are used as surro-
gates for diagnosis and recurrence dates followed by a
refining process that involves back-dating interval
optimization to improve correlation.
There are some crucial considerations in defining the
key time points both for the manual data and routine
data interpretation: 1. Manual diagnosis dates: These
followed a hierarchy with imaging following the pre-
ferred diagnostic biopsy date due to certain limitations:
Whilst imaging can give a strong indication of
a
b
Fig. 2 a Kaplan Meier Curve for PFS (in months). Survival curves for the routine (green line) and manual (blue line) data are shown. 27/43 events
censored from the manual data and 31/43 events censored from the routine data. Wilcoxon signed-ranks test statistic 1.10, p(0.29). b Kaplan Meier
Curve for OS (in months). Survival curves for the routine (green line) and manual (blue line) data are shown. 27/43 events censored from the manual
data and 30/43 events censored from the routine data. Wilcoxon signed-ranks test statistic 0.08, p(0.78)
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malignancy, patients with lung cancer often have back-
ground lung disease that makes them prone to recurrent
chest infections. Radiological changes seen during active
chest infections make identifying malignancy less reli-
able. This is in contrast to identifying recurrence and/or
metastatic disease when malignancy is already known,
and diagnosis is often done radiologically without repeat
biopsies, unless diagnosis is uncertain. 2. Manual and
routine recurrence interval dates: Taken to be the date
of progression, recurrence, metastases, death, or last
known clinical encounter (if no progression occurred)
for practical reasons- so that events would be reached. 3.
Identifying secondary treatment in routine data: Any
therapy starting after a 10 week interval from the last
day of radiotherapy or chemotherapy (whichever was
completed last) was chosen as an indicator of secondary
treatment because it is standard practice for patients to
have reassessment imaging at 8–12 weeks following
completion of treatment. At this point, progressive or
metastatic disease can be observed so a 10 week interval
was selected as a compromise- too short an interval
might pick up delayed primary treatment events, and
too long an interval might miss the start of secondary
treatment.
OS and PFS values derived from our routine data
methodology correlated well with that derived from the
gold standard manual data with the Wilcoxon signed-
rank test results suggesting no statistically significant
difference between the survival curves when assessed by
manual versus routine data. Based on the manual
data, the median PFS and OS was 10.78 months and
16.36 months, respectively. Using the proxy measures
from the routine data, the estimated median PFS and OS
was 10.68 months and 15.38 months, respectively. The
paired sample t-tests showed the difference in the mean
PFS to be small and non-significant but the difference in
the mean OS to be larger and significant. However, these
results correlated well overall with the manual data, giving
a statistically significant correlation coefficient of 0.94 for
PFS and 0.97 for OS. The high sensitivity and specifi-




Fig. 3 a. Correlation between manual and routine derived PFS
intervals. Correlation coefficient of 0.94, p < 0.0001. Solid line
represents the line of best fit for the data points. Dashed line
represents the correlation line if the manual and routine data were
equal. Outliers are circled and identified with their patient number
corresponding to Table 3. b Correlation between manual and
routine derived OS intervals. Correlation coefficient of 0.97, p < 0.0001.
Solid line represents the line of best fit for the data points. Dashed line
represents the correlation line if the manual and routine data were
equal. Outliers are circled and identified with their patient number
corresponding to Table 3. c Correlation between manual and routine
dates of diagnosis. Correlation coefficient of 0.98, p < 0.0001. Solid line
represents the line of best fit for the data points
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data does not tend to falsely identify recurrence or
death events so survival estimates are less likely to be
underestimated.
All discrepancies between the manual and routine data
sets could be attributed to 1.Missing or inaccurately en-
tered OPCS or ICD10 codes due to a) patients having
diagnosis and/or recurrence detected with treatment ini-
tiation in other hospitals b) codes appearing on patients’
admission dates rather than the dates of the procedures
themselves or c. treatment of recurrence being non-
standard (eg. oligometastatic disease being treated surgi-
cally) and 2. Delays in initiation of treatment beyond the
NHS England target of 31 days due to, for example, pa-
tients becoming unwell, resulting in alternative surro-
gates having to be used for dates of diagnosis or
recurrence. The reasons for deaths escaping detection
on routine data were mostly unclear although 1 patient
died abroad, a situation that is perhaps less reliably up-
dated on to the system. However, there is a time lag be-
tween the occurrence of death and its record being
updated on the system, and it is possible that this af-
fected the ability to detect death events on routine data.
These all led to late diagnosis dates, late or absent recur-
rence dates, and/or absent death dates and subsequently
inaccurately calculated PFS and OS. Although this re-
sulted in an increased censoring of events and a separ-
ation of the survival curves, the differences were not
statistically significant (Fig. 2a and b).
Our back-dating strategy, used to optimize correlation
between manual and routine primary diagnosis and re-
currence event dates, utilized time intervals tailored to
reflect clinical practice and the clinical target times set
out by NHS England (2013). This framework recom-
mends that the maximum time from diagnosis to first
definitive treatment is 1 month (or 31 days); and that for
all subsequent treatments for new cases or primary and
recurrent cancer, the maximum time interval is 1 month
(or 31 days). Therefore, ICD10 codes consistent with a
primary diagnosis or recurrent, progressive or metastatic
disease, are likely to be preceded by diagnostic investiga-
tion codes within a period of up to 31 days. A longer
interval of 6 weeks was chosen to avoid potentially miss-
ing relevant investigative and diagnostics flag for pa-
tients who may have started treatment beyond the
31 day target. This meant we still captured patients who
may have had delays in starting treatment due to 1.pa-
tients’ choice 2.becoming unwell 3.radiotherapy re-
planning requirements resulting from significant
changes in anatomy or 4.an inability to start in the pre-
ferred time period due to patient load exceeding treat-
ment capacity at that time.
The completeness of recorded information is a funda-
mental limitation of both manual and routine data.
Manual data not only most reliably determines outcome
measures but contains important details such as histo-
logical subtype, mutation status, lung function, detailed
smoking status (ex-smoker, recent ex-smoker, and quan-
tification by pack-years), response to treatment demon-
strated on CT (stable disease, partial response,
progressive disease), and grading of side effects from
treatment. At present such information can only be
identified in manual data as these are not coded in
routine data. However, clinical outcome measures can
be inferred or used as proxy indicators. For example, it
would be reasonable to assume that ICD10 codes for
oesophagitis or neutropenia in a patient receiving
chemotherapy and radiotherapy might be experiencing
these side effects as a direct result from their treatment.
The caveat is that there may be confounding factors or
comorbidities causing these problems, the severity of
these side effects are not coded, and the absence of these
ICD-10 codes does not mean they were not experienced.
Adverse effects from treatment have an important im-
pact on patients’ ability to complete treatment and their
quality of life.
Additional limitations include potentially confusing
routine information for patients who have other syn-
chronous or metachronous malignancies (eg. head and
neck and bladder cancers) where recurrences and treat-
ment may occur. For these patients with dual pathology,
where “Secondary & unspecified malignant neoplasm of-
” or “Secondary malignancy of-” codes appear in the
HES data, referring to the RTDS and SACT data can
help distinguish if treatment is being initiated for disease
relating to the lung cancer or to the other malignancy as
1) the RTDS data will state the site being treated and the
relevant ICD-10 diagnosis code relating to that treat-
ment (eg. Pelvic metastases from a lung cancer primary
will have “pelvis” documented as the treatment site and
an ICD10 code denoting a lung cancer primary) 2) the
SACT data would inform us as to what chemotherapy is
being delivered (which, in itself, might be indicative of
the primary, if the regime is exclusive to lung cancer)
and the primary diagnosis relating to that chemotherapy
regime.
Interestingly, although it is well recognized that PS im-
pacts OS [2, 15, 17], is used to help determine the most
appropriate management course [18], and is required to
be recorded in manual and routine databases, this ap-
pears to be poorly recorded in both. This perhaps re-
flects a view that the usefulness of a PS score is limited
by the degree of subjectivity and inter-observer variabil-
ity in assessment [17, 19].
There has been a recognized need to improve the
quality of routine data in order to broaden its clinical
application. An example of one such database devel-
oped for quality improvement is the Cancer Out-
comes and Service Dataset (COSD) that has recently
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been introduced as the new national standard for
reporting cancer in the NHS in England, having re-
placed the National Cancer Dataset. This system will
enable the clinical details and outcomes from multi-
disciplinary team meetings (where all patients diag-
nosed with and being considered for cancer treatment
are discussed) to be entered in to COSD. This has
begun to be in use in our hospital and one of the
changes this will have on outcomes analysis will be to
ascertain a more accurate diagnosis date.
In addition, national cancer strategies [4, 20] have
placed increasing emphasis on recording of clinical
outcome measures to help monitor if national targets
are being met which will drive the enrichment of the
available clinical databases, and focus more attention
on developing methods to analyse routine datasets.
This will not only promote the clinical usefulness of
routine data for survival outcomes but potentially for
treatment toxicity and patient-screening for entry
into trials.
Future work includes integrating new national data-
sets and testing our method on a larger cohort to see
if accuracy can be improved. Whilst the identified
event flags used as proxy measures and the chosen
back-dating intervals reflect our local practice, we
have deliberately ensured they are not specific to it
such that this method is transferable to other centres.
As the management of NSCLC in the UK is standard-
ized by NICE guidelines any nuances in practice
across the country are unlikely to limit the applica-
tion of this technique although adjustments for
optimization may be required. Once this technique
has been sufficiently refined, a computational algo-
rithm will be developed to automate this process such
that large scale routine data can be processed more
efficiently.
Conclusions
This is a novel approach that uses routine datasets to
determine outcome indicators in patients with LA
NSCLC that has the potential to be a reliable surro-
gate to analyse manual data, having demonstrated a
Pearson correlation coefficient of 0.94 for PFS, and
0.97 for OS. An algorithm is being developed to en-
able automated interpretation of routine datasets for
patients with LA NSCLC and is being refined to im-
prove data correlation. The clinical application of au-
tomated routine data interpretation goes beyond
assessing survival data in LA NSCLC, and can be
tailored to auto-analyse outcomes for other stages of
NSCLC and/or other tumour types. The ability to
enable efficient and large scale analysis of current
lung cancer strategies has a huge potential impact
on the healthcare system.
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